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Correction: Reduced expression of AMPK-ß1 during
tumor progression enhances the oncogenic
capacity of advanced ovarian cancer
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Correction
After publication of this article [1] the authors noticed
an error in Figure 5A, B and D (Figure 1 here). In Figure
5A (Figure 1 here), the same image from AMPK-β1w a s
erroneously used for pAMPKα of A2780cp- β1 panel.
The correct image for pAMPKα is now provided. In
Figure 5B and D (Figure 1 here), the panel of OV2008-sh
β1 used two different sets of b-actin. The b-actin in Figure
5B (Figure 1 here) is now used for the whole panel of
OV2008-sh β1i nF i g u r e5 Ba n dD( F i g u r e1h e r e ) .T h e s e
errors were unintentionally made during figure prepa-
ration and do not in any way alter the results or conclu-
sions of this study. The authors apologize that these errors
were not detected earlier.
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Li et al. Molecular Cancer 2014, 13:161
http://www.molecular-cancer.com/content/13/1/161Figure 1 AMPK-β1 positively regulates AMPK but negatively modulates AKT/mTOR, ERK and JNK activities. (A) AMPK-β1 overexpression
in A2780cp (C4, C5 and C11) and SKOV3 (C1, C2 and C3) cells activated AMPK (increased pAMPKα and pACC (left panel)) but reduced AKT (pAKT)
and mTOR (pmTOR and pP70S6K) activities (right panel). (B) Knockdown of AMPK-β1 in OV2008 (C2, C5 and C32) and OVCA433 (C1, C12 and
C23) cells by shRNA suppressed AMPK activity (decrease of pAMPKα and pACC (left panel)) but elevated AKT (pAKT) and mTOR (pmTOR and
pP70S6K) activities (right panel). (C) AMPK-β1 overexpression sensitizes ovarian cancer cells to an AMPK activator, metformin, during AMPK
activation. SKOV3 cells were treated with the AMPK activator, metformin, at 0-, 2-, and 10-mM concentrations. Stable clones overexpressing
AMPK-β1 (C1, C2, C4, and C5) were more sensitive to metformin (2 mM) in the presence of elevated pAMPKα compared with the two empty
vector controls (V2 and V3). (D) Depletion of AMPK-β1 activates the ERK and JNK pathways, and knockdown of AMPK-β1 in OV2008 (C2, C5 and
C32) and OVCA433 (C1, C12 and C23) cells led to an increase in JNK (pJNK) and ERK (pERK) signaling activities.
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